Guidance Recipients

Match would-be startups with local industry, academia, and related institutions

Anticoagulant Leukocyte-Depleting Filter

Chang Yung, Chung Yuan Christian University
Year 2015Year Period:2015-06-01 to 2017-02-28

Overview

  • It is not uncommon for blood transfusion to cause side effects and complications, such as non-hemolytic febrile transfusion reactions and transfusion-associated graft-versus-host disease.
  • Zwitterionic-bias material modification technology is employed to bolster the filter’s specificity for leukocyte removal and minimize red blood cell rupture and platelet activation, thereby enhancing transfusion safety.
  • With a leukocyte removal rate of over 99.9%, this filter has proven effective in mitigating the side effects of transfusion.

Development Process

普瑞博生技 靠左 有字.png (12 KB)

Over the course of this project under the Applied Research Incubation Program, the team completed the following: design and manufacturing of a general-use leukocyte-depleting filter, preclinical trials, and establishment of a self-sufficient capacity for making critical experimental instruments needed in filter production, based on which the parameters for machinery design can be induced, analyzed, and formulated. After PuriBlood Medical Co., Ltd. was established on January 27, 2016, the team continued to offer assistance in product commercialization.

Milestones

2021
  • Obtained sale certification in Vietnam, Thailand, and Burma.
2020
  • Won the Hsinchu Science Park Innovation Product Award.
  • Obtained CE mark.
2019
  • TFDA approved.
  • Collaborate with Chung Yuan Christian University.
2017
  • Obtained FDA approval.
  • Entered the Science Park.
2016
  • Formed Puriblood Medical Co., Ltd.
  • Won National Innovation Award.
2014
  • Admission to the MOST’s Nursery Program
2012
  • Received Germination Program funding.
Back to List